PEPG insider filings
PepGen Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-17. Screen PEPG transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 5 insiders — 8,625,000 shares, $43,125,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 8,625,000 shares @ $5.00 ($43,125,000) by RA CAPITAL MANAGEMENT, L.P., filed 2026-11-17.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner & RA Capital Healthcare Fund LP — Director, 10% owner & RA Capital Nexus Fund II, L.P. — Director & Kolchinsky Peter — Director, 10% owner & Shah Rajeev M. — Director, 10% owner | 1 | 1 leg · 8,625,000 sh · $43,125,000 | — | — |
Recent insider filings — PepGen Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 8,625,000 @ $5 | EDGAR |
| 2026-06-22 | 4 | Wyman Lisa — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Mayer Howard — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Resnick Joshua — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Dable Habib J — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | KEATING LAURIE — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Finer Mitchell H. — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | HENSON HEIDI — Director | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Kasraian Kasra — Chief Technical Officer | Sale (S): 1,233 @ $1.41 | EDGAR |
| 2026-03-06 | 4 | Donnelly Noel — Chief Financial Officer | Sale (S): 2,032 @ $6.23 · Sale (S): 52 @ $6.33 | EDGAR |
| 2026-03-06 | 4 | McArthur James G — President and CEO, Director | Sale (S): 5,144 @ $6.23 · Sale (S): 131 @ $6.33 | EDGAR |
| 2026-03-06 | 4 | STRECK PAUL — EVP, Head of R&D | Sale (S): 1,832 @ $6.23 · Sale (S): 47 @ $6.29 | EDGAR |
| 2026-03-02 | 4 | Kasraian Kasra — Chief Technical Officer | Grant/award (A): 34,557 @ $0 · Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Donnelly Noel — Chief Financial Officer | Grant/award (A): 76,793 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | McArthur James G — President and CEO, Director | Grant/award (A): 187,688 @ $0 · Grant/award (A): 731,250 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | STRECK PAUL — EVP, Head of R&D | Grant/award (A): 50,300 @ $0 · Grant/award (A): 196,500 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Grant/award (A): 30,717 @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Donnelly Noel — Chief Financial Officer | Disposition to issuer (D): 203,339 (derivative) @ $0 · Grant/award (A): 203,339 (derivative) @ $0 · Disposition to issuer (D): 169,037 (derivative) @ $0 · Grant/award (A): 169,037 (derivative) @ $0 · Disposition to issuer (D): 144,000 (derivative) @ $0 · Grant/award (A): 144,000 (derivative) @ $0 · +2 more | EDGAR |
| 2025-12-18 | 4 | McArthur James G — President and CEO, Director | Disposition to issuer (D): 352,705 (derivative) @ $0 · Grant/award (A): 352,705 (derivative) @ $0 · Disposition to issuer (D): 40,815 (derivative) @ $0 · Grant/award (A): 40,815 (derivative) @ $0 · Disposition to issuer (D): 40,815 (derivative) @ $0 · Grant/award (A): 40,815 (derivative) @ $0 · +8 more | EDGAR |
| 2025-12-18 | 4 | STRECK PAUL — EVP, Head of R&D | Disposition to issuer (D): 202,816 (derivative) @ $0 · Grant/award (A): 202,816 (derivative) @ $0 · Disposition to issuer (D): 40,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Vittiglio Joseph — Chief Business & Legal Officer | Grant/award (A): 35,000 @ $0 · Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | Oxford Science Enterprises plc | Purchase (P): 200,000 @ $3.20 | EDGAR |
| 2025-09-30 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Purchase (P): 9,375,000 @ $3.20 | EDGAR |
| 2025-06-06 | 4 | Mayer Howard — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Resnick Joshua — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Dable Habib J — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | KEATING LAURIE — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | HENSON HEIDI — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | STRECK PAUL — EVP, Head of R&D | Purchase (P): 8,375 @ $1.24 | EDGAR |
| 2025-05-21 | 4 | Kasraian Kasra — Chief Technical Officer | Grant/award (A): 16,750 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-04-22 | 4 | McArthur James G — President and CEO, Director | Purchase (P): 10,000 @ $1.35 | EDGAR |
| 2025-04-09 | 4 | McArthur James G — President and CEO, Director | Purchase (P): 41,500 @ $1.15 | EDGAR |
| 2025-03-31 | 4 | Wyman Lisa — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-03-31 | 4 | Finer Mitchell H. — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Donnelly Noel — Chief Financial Officer | Grant/award (A): 23,283 @ $0 · Grant/award (A): 104,250 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | McArthur James G — President and CEO, Director | Grant/award (A): 60,719 @ $0 · Grant/award (A): 271,875 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | STRECK PAUL — EVP, Head of R&D | Grant/award (A): 19,430 @ $0 · Grant/award (A): 87,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | DeLena Mary Beth — General Counsel | Grant/award (A): 13,400 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Donnelly Noel — Chief Financial Officer | Grant/award (A): 3,200 @ $0 · Sale (S): 1,527 @ $1.68 | EDGAR |
| 2025-02-26 | 4 | DeLena Mary Beth — General Counsel | Grant/award (A): 3,000 @ $0 · Sale (S): 1,432 @ $1.68 | EDGAR |
| 2024-08-20 | 4 | STRECK PAUL — EVP, Head of R&D | Grant/award (A): 202,816 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-07-26 | 4 | Mellion Michelle L — Chief Medical Officer | Option exercise (M): 201 @ $10.21 · Sale (S): 201 @ $18.01 · Option exercise (M): 7,571 @ $10.21 · Sale (S): 7,571 @ $18.06 · Option exercise (M): 201 (derivative) @ $0 · Option exercise (M): 7,571 (derivative) @ $0 | EDGAR |
| 2024-07-19 | 4 | Mellion Michelle L — Chief Medical Officer | Option exercise (M): 12,625 @ $10.21 · Sale (S): 12,625 @ $18.20 · Option exercise (M): 12,625 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Mellion Michelle L — Chief Medical Officer | Option exercise (M): 3,288 @ $10.21 · Sale (S): 3,288 @ $18.04 · Option exercise (M): 5,901 @ $10.21 · Sale (S): 5,901 @ $18.00 · Option exercise (M): 3,288 (derivative) @ $0 · Option exercise (M): 5,901 (derivative) @ $0 | EDGAR |
| 2024-07-03 | 4 | Mellion Michelle L — Chief Medical Officer | Option exercise (M): 875 @ $10.21 · Sale (S): 875 @ $18.01 · Option exercise (M): 37 @ $10.21 · Sale (S): 37 @ $18.07 · Option exercise (M): 875 (derivative) @ $0 · Option exercise (M): 37 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | Mellion Michelle L — Chief Medical Officer | Option exercise (M): 9,260 @ $10.21 · Sale (S): 9,260 @ $18.19 · Option exercise (M): 9,260 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | HENSON HEIDI — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — PepGen Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PEPG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs